In terms of medication, more patients in the OCAD(MetS+) group used oral or injected insulin, biguanides, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) (all p < 0.01). The gene discussed is ACE; the disease is metabolic syndrome.